ERBB2 and endometrial cancer: Despite these limitations, this study leverages a large, well-characterized cohort with comprehensive genomic profiling, enabling detailed evaluation of CNH endometrial cancers and MECOM, CCNE1, and ERBB2 gene amplifications.